HCM
LXRX icon

Highbridge Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Highbridge Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-544,812
Closed -$7.81M – 1444
2017
Q1 		$7.81M Buy
+544,812
New +$8.08M 0.11% 230
2016
Q1 		– Sell
-40,168
Closed -$534K – 1677
2015
Q4 		$534K Buy
+40,168
New +$494K 0.01% 973

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Highbridge Capital Management's LXRX Position: Q2 2017 in Review

Highbridge Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 544,812 shares — an estimated $7.81M sold.

Highbridge Capital Management first reported a position in LXRX in Q4 2015 and held it in 2 quarters. The position peaked at $7.81M in Q1 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

  • Highbridge Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 544,812 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $7.81M.
  • Highbridge Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Highbridge Capital Management's Lexicon Pharmaceuticals position peaked at $7.81M in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.